VBP
The Antidote - Taking a Look at Corporate Inversions and e-Health
October 10 by Pharmaceuticals & Biotechnology EditorSummer is at an end and whilst corporate activity continued apace, including AbbVie acquiring Shire, Omega Pharma attracting acquisition interest, and GSK and Sanofi seeking to dispose of certain of...
Value Based Pricing for the NHS- An Interview with NICE Chief Executive Sir Andrew Dillon
September 02 by Gerald ClarkeThe National Institute for Health and Care Excellence (NICE) will be taking a central role in Value Based Pricing (VBP) for the NHS starting in 2014. To find out more about this, Pharma IQ...
The 4 Biggest Battles in Drug Pricing
May 10 by Gerald ClarkeThe global financial atmosphere in the past years has catalysed many changes in the relationship between the pharma industry and governments. In a fiscally constrained environment it is unsurprising...
Value-Based Pricing in 2012 – Is it Still Worth the Trouble?
February 08 by Stuart Carroll & Alasdair WilliamsAs the old aphorism goes, a New Year means a new beginning. It also provides an opportunity for all of us to make New Year resolutions – promises we make to one or more lasting personal goals, p...
Value Based Pricing for the NHS- An Interview with NICE Chief Executive Sir Andrew Dillon
March 29 by Andrew DillonGerald Clarke: I’m Gerald Clarke, Editor at Pharma IQ. Today I’m joined by Sir Andrew Dillon, Chief Executive of the National Instit...